title: Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.
abstract: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease and it represents the hepatic manifestation of metabolic syndrome, which includes type 2 diabetes mellitus (T2DM), dyslipidemia, central obesity and hypertension. Glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors were widely used to treat T2DM. These agents improve glycemic control, promote weight loss and improve lipid metabolism. Recent studies have demonstrated that the GLP-1 receptor (GLP-1R) is present and functional in human and rat hepatocytes. In this review, we present data from animal researches and human clinical studies that showed GLP-1 analogues and DPP-4 inhibitors can decrease hepatic triglyceride (TG) content and improve hepatic steatosis, although some effects could be a result of improvements in metabolic parameters. Multiple hepatocyte signal transduction pathways and mRNA from key enzymes in fatty acid metabolism appear to be activated by GLP-1 and its analogues. Thus, the data support the need for more rigorous prospective clinical trials to further investigate the potential of incretin therapies to treat patients with NAFLD.
authors.affiliation: Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China.|Department of Endocrinology, Jinan, China.
authors.forename: Chao-Lin
authors.initials: CL
authors.lastname: Li
authors.affiliation: Hemodialysis Center, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, 264000, China.
authors.forename: Lu-Jie
authors.initials: LJ
authors.lastname: Zhao
authors.affiliation: Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China.
authors.forename: Xin-Li
authors.initials: XL
authors.lastname: Zhou
authors.affiliation: Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China.
authors.forename: Hui-Xiao
authors.initials: HX
authors.lastname: Wu
authors.affiliation: Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China. jjzhao@medmail.com.cn.
authors.forename: Jia-Jun
authors.initials: JJ
authors.lastname: Zhao
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D050356:Lipid Metabolism / Q000187:drug effects; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy* / Q000378:metabolism; D014280:Triglycerides / Q000378:metabolism
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D014280:Triglycerides; D052216:Glucagon-Like Peptide 1